The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006

Annals of Oncology

Volumn 18, Issue SUPPL. 7, 2007, Pages

  Verslype, C ^a   Van Cutsem, Eric ^a   Dicato, M ^b   Cascinu, S ^c   Cunningham, D ^d   Diaz Rubio, E ^e   Glimelius, B ^f,z   Haller, D ^g   Haustermans, K ^a   Heinemann, V ^h   Hoff, P ⁱ   Johnston, P G ^j   Kerr, D ^k   Labianca, R ^l   Louvet, C ^m   Minsky, B ⁿ   Moore, M ^o   Nordlinger, B ^p   Pedrazzoli, S ^q   Roth, A ^r   Rothenberg, M ^s   Rougier, P ^p   Schmoll, H J ^t   Tabernero, J ^u   Tempero, M ^v   van de Velde, C ^w   Van Laethem, J L ^x   Zalcberg, J ^y   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Luxembourg Medical Center   (Luxembourg)

^c Azienda Ospedaliera Umberto I   (Italy)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f UPPSALA UNIVERSITY   (Sweden)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ HOSPITAL SÍRIO LIBANÊS   (Brazil)

^j QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l OSPEDALI RIUNITI   (Italy)

^m HÔPITAL SAINT ANTOINE   (France)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o UNIVERSITY OF TORONTO   (Canada)

^p HÔPITAL AMBROISE PARÉ   (France)

^q UNIVERSITY OF PADOVA   (Italy)

^r GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^s VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^t MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^u HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^x ERASME HOSPITAL   (Belgium)

^y UNIVERSITY OF MELBOURNE   (Australia)

^z KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Adjuvant treatment; Chemotherapy; Pancreatic cancer; Radiotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; MITOMYCIN C; MORPHINE; MORPHINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PANCREAS ENZYME; PLATINUM DERIVATIVE; STREPTOZOCIN;

ADJUVANT THERAPY; BILE DUCT OBSTRUCTION; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG CHOICE; DRUG EFFICACY; DUODENUM OBSTRUCTION; ENDOSCOPIC ECHOGRAPHY; EVIDENCE BASED MEDICINE; HEALTH CARE PERSONNEL; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREAS RESECTION; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY CONTROL; QUALITY OF LIFE; SPAIN; STENT; SURVIVAL TIME; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR;

COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; PANCREATIC NEOPLASMS;

EID: 35148834395     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm210     Document Type: Conference Paper

References (86)

1. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997; 349: 485-489.
2. Parkin DM, Bray Fl, Devessa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): 4-66.
3. Lowenfels AB, Maisonneuve P. Epidemiologic and etiologic factors of pancreatic cancer. Hematol Oncol Clin North Am 2002; 16: 1-16.
4. Petersen GM, de Andrade M, Goggins M et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2006; 15: 704-710.
5. Pisters PW, Wolff RA, Crane CH et al. Combined-modality treatment for operable pancreatic adenocarcinoma. Oncology 2005; 19: 393-404.
6. Ariyama J, Suyama M, Satoh K, Sai J. Imaging of small pancreatic ductal adenocarcinoma. Pancreas 1998; 16: 396-401.
7. Tempero MA, Behrman S, Ben-Josef E et al. Pancreatic adenocarcinoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3: 598-626.
8. Ridder GJ, Klempnauer J. Back pain in patients with ductal pancreatic cancer: Its impact on resectability and prognosis after resection, Scand J Gastroenterol 1995; 30: 1216-1220.
9. Legman P, Vignaux O, Dousset B et al. Pancreatic tumors: Comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998; 170: 1315-1322.
10. Ichikawa T, Haradome H, Hachiya J et al. Pancreatic ductal adenocarcinoma: Preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997; 202: 655-662.
11. Harewood GC, Wiersema LM, Halling AC et al, Influence of EUS training and pathology interpretation on accuracy of EUS-guided fine needle aspiration of pancreatic masses. Gastrointest Endosc 2002; 55: 669-673.
12. John TG, Greig JD, Carter DC et al. Carcinoma of the pancreatic head and periampullary region: Tumour staging with laparoscopy and laparoscopic ultrasonography. Ann Surg 1995; 221: 156-164.
13. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-1723.
14. Safi F, Schlosser W, Falkenreck S, Beger HG. CA19-9 serum course and prognosis of pancreatic cancer. Int J Pancreatol 1996; 20: 155-161.
15. UICC. TNM classification of malignant tumours. Sobin LH, Wittekind CH (eds): 6th edition. Hoboken, NJ: John Wiley & Sons 2002.
16. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 6th edition.. Philadelphia, PA: Lippincott Williams & Wilkins 2001; 1126-1161.
17. Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: Definitions, management and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046.
18. Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
19. Pedrazzoli S, DiCarlo VI, Dionigi R et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228: 508-517.
20. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59-66.
21. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2001; 5: 681.
22. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resecton of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-277.
23. Kalser MM, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
24. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled prospective, randomised multicentre study. Eur J Cancer 1993; 29: 698-703.
25. Klinkenbijl JH, Jekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-Fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-784.
26. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 2006; 244: 332-333.
27. Kosuge T, Kiuchi T, Mukai K, Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006; 36: 159-165.
28. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
29. Regine WF, Winter KW, Abrams R et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 2006; 24 (Suppl 18S): (Abstr 4007).
30. Wolff R, Evans D, Crane C et al. Initial results of preoperative gemcitabine based chemoradiation for resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2002; 21: 130a (Abstr 516).
31. Ballinger AB, McHugh M, Catnach SM et al. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut 1994; 35: 467-470.
32. Anderson JR, Sorensen SM, Kruse A et al. Randomized trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30: 1132-1135.
33. Shepherd HA, Royle G, Ross AP et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: A randomid trial. Br J Surg 1988; 75: 1166-1168.
34. Smith AC, Dowsett JF, Russell RC et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 1994; 344: 1655-1660.
35. Taylor MC, McLeod RS, Langer B. Biliary stenting versus bypass surgery for the palliation of malignant distal bile duct obstructon: A meta-analysis. Liver Transpl 2000; 6: 302-308.
36. Cotton PB, Randomization is not the (only) answer: A plea for structured objective evaluation of endoscopic therapy. Endoscopy 2000; 32: 402-405.
37. Schassmann A, von Gunten E, Knuchel J et al. Wallstents versus plastic stents in malignant biliary obstruction: Effects of stent patency of the first and second stent on patient compliance and survival. Am J Gastroenterol 1996; 91: 654-659.
38. Libby ED, Leung JW. Prevention of biliary stent clogging: A clinical review. Am J Gastroenterol 1996; 91: 1301-1308.
39. Davids PH, Groen AK, Rauws EA et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992; 340: 1488-1492.
40. Knyrim K, Wagner HJ, Pausch J, Vakil N. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy 1993; 25: 207-212.
41. Prat F, Chapat O, Ducot B et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998a; 47: 1-7.
42. Prat F, Chapat O, Ducot B et al. Predictive factors for survival of patients with inoperable malignant distall biliary strictures: A practical management guideline. Gut 1998b; 42: 76-80.
43. Pereira-Lima JC, Jakobs R, Maier M et al. Endoscopic biliary stenting for the palliation of pancreatic cancer: Results, survival predictive factors, and comparison of 10-French with 11.5-French gauge stents. Am J Gastroenterol 1996; 91: 2179-2184.
44. Carr-Locke DL. Role of endoscopic stenting in the duodenum. Ann Oncol 1999; 10: S261-S264.
45. Reddy SK, Zhou LL. Celiac plexus block versus systemic opioid medication in the management of pancreatic cancer pain. In Evans DB, Pisters PWT, Abbruzzese JL (eds): Pancreatic cancer. New York, NY: Springer-Verlag 2002; 223-231.
46. Rykowski JJ, Hilgier M. Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: Influence on pain relief. Anesthesiology 2000; 92: 347-354.
47. Gunaratnam NT, Sarma AV, Norton ID et al. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc 2001; 54: 316-324.
48. Holland JC, Korzun AH, Tross S et al. Comparative psychological disturbance in patients with pancreatic and gastric cancer. Am J Psychiatry 1986; 143: 982-986.
49. Bruno MJ, Haverkort EB, Tijssen GP et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998; 42: 92-96.
50. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
51. Kroep J, Pinedo H, Van Groeningen C et al. Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 1999; 10: S234-S238.
52. André T, Lotz JP, Bouleuc C et al. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 1996; 7: 173-178.
53. Ducreux M, Rougier P, Pignon JP et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002; 13: 1185-1191.
54. Abbruzzese JL. Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol 1996; 23: 25-31.
55. Casper E, Green M, Kelsen D. Phasic II trial of gemcitabine (2,2-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
56. Carmichael J, Fink U, Russel RC et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-105.
57. Storniolo A, Enas N, Brown C et al. An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 85: 1261-1268.
58. Burris H, Moore M, Anderson J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
59. Tempero M, Plunkett W, Ruiz van Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-3408.
60. Poplin E, Levy D, Berlin J et al. Phase III trial of gemcitabine (30 min infusion) versus gemcitabine (fixed-dose rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006; 24 (Suppl 18): (Abstr LBA4004).
61. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783.
62. O'Reilly EM, Abou-Alfa GK, Letourneau R et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine vs. gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2004; 22 (Suppl 14): (Abstr 4006).
63. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645.
64. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952.
65. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
66. Cunningham D, Chau I, Stocken C et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005; 3 (Suppl 4): (Abstr PS11).
67. Herrmann R, Bodoky G, Rushstaller T et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer: A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2005; 23 (Suppl 16): (Abstr 4010).
68. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patents with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002; 20: 3270-3275.
69. Di Costanzo F, Carlini P, Doni L et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: A randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005; 93: 185-189.
70. Riess H, Helm A, Niedergethmann M et al. A randomised, prospective, multicentre, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 1092 (Abstr 4009).
71. Heineman V, Hinke A, Böck S, Louvet C. Meta-analysis of randomized trials: Evaluation of benefit of chemotherapy from combination chemotherapy applied in advanced pancreatic cancer. Ann Oncol 2006; 17 (Suppl 9): 226.
72. Milella M, Carlini P, Gelibter A et al. Does a second drug added to gemcitabine (G) improve outcome over G in advanced pancreatic cancer (APC)? a pooled analysis of 5561 patients enrolled in 16 phase III trials. Ann Oncol 2006; 17 (Suppl 9): 226-227.
73. Moore M, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
74. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patents with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-167.
75. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
76. Kindler HL, Niedzwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and leukemia Group B (CALBG) 80303. Proceedings of the ASCO Gastrointestinal Cancers Symposium 2007 (Abstr 108).
77. Van Cutsem E, Verslype C, Grusenmeyer PA. Lessons learned in the management of pancreatic cancer [editorial]. J Clin Oncol 2007; 25: 1949-1952.
78. Mitry E, Ducreux M, Ould-Kaci M et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol 2006; 30: 357-363.
79. Gunderson LL, Martin JK, Kvols LK et al. Intraoperative and external beam irradiation ± 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1987; 13: 319-329.
80. Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710.
81. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751-755.
82. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs, gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol 2006; 24 (Suppl 18): (Abstr 4008).
83. Huguet F, André T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III Studies. J Clin Oncol 2007; 20: 326-331.
84. Schneider BJ, Ben-Josef E, McGinn CJ et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer, Int J Radiat Oncol Biol Phys 2005; 63: 1325-1330.
85. Sa Cunha A, Rault A, Laurent C et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 2005; 201: 359-365.
86. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006; 12: 5277-5287.